Navigation Links
A Significant Share of Surveyed Treatment-Naive and Prior Failure HCV Patients Plan to Initiate an HCV Treatment Regimen in the Next Year
Date:9/9/2013

progression and reversal, and achieving sustained virologic response as the most important attributes in an HCV regimen, while exclusion of interferon or ribavirin was perceived as least important. Our research reveals that most HCV patients are prepared to endure a certain level of temporary disability as long as the treatment is efficacious."

Of note, surveyed treatment-naive HCV patients overall believe they have more influence on the management and treatment of their infection than their treating physicians. Also, the level of perceived personal influence over treatment decisions is significantly higher among surveyed treatment-naive patients than among treatment-experienced patients.

PatientTrends®: Hepatitis C Virus (US) 2013 is an annual report that includes data from 245 chronically-infected HCV patients and provides insight into patient demographics, patient-physician relationship, treatment history and plans to initiate treatment. The report also investigates the importance of drug attributes to patients, satisfaction with currently-available HCV therapies and awareness of emerging therapies, including AbbVie's ABT-267, ABT-333 and ABT-450, Boehringer Ingelheim's deleobuvir and faldaprevir, Bristol-Myers Squibb's asunaprevir and daclatasvir, Janssen/Medivir's simeprevir and Gilead's sofosbuvir and ledipasvir.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class,
'/>"/>

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
3. "AWAKEN" Survey Finds Only 50 Percent of Americans Understand Significant Health Impact of Narcolepsy, and Many Physicians Not Comfortable Diagnosing the Sleep Disorder
4. Kewaunee Scientific Reports Significantly Improved Results for Fourth Quarter
5. South Carolinas Stop-Sale System Achieves Significant Results In Battle Against Meth
6. Tennessee Stop-Sale System Achieves Significant Results In Battle Against Meth
7. Indianas Stop-Sale System Achieves Significant Results In Battle Against Meth
8. Alabamas Stop-Sale System Achieves Significant Results In Battle Against Meth
9. Missouri Stop-Sale System Achieves Significant Results In Battle Against Meth
10. Kansas Stop-Sale System Achieves Significant Results In Battle Against Meth
11. Illinois Stop-Sale System Achieves Significant Results In Battle Against Meth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  According to Millennium Research Group (MRG), the global ... the United States and European transcatheter ... moderately through 2022, with embolization particles representing one ... in drug-eluting beads (DEBs) and radioembolization spheres in ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/14/2014)... InformEx, North America,s leading business ... hold the 30 th edition of its annual conference ... from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... chemical and specialty chemical companies will take part in the ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
(Date:4/17/2014)... led by researchers at UC Davis has shown that ... role in cell division, also boosts the mitochondrial activity ... the complex has been shown to perform both jobs. ... target to control cellular energy production, potentially advancing cancer ... today in the journal Developmental Cell . , ...
(Date:4/17/2014)... international research team led by Cesar A. Arias, M.D., ... at Houston (UTHealth) has identified a new superbug that ... report appeared in the April 17 issue of ... new superbug is part of a class of highly-resistant ... MRSA, which is a major cause of hospital and ...
(Date:4/17/2014)... not uncommon these days to find a colored ribbon representing ... breast cancer. But what color ribbon does one think of ... designated color, for many suffering from the disease, black may ... University study consisting of lung cancer patients, primarily smokers between ... more light on the stigma often felt by these patients, ...
(Date:4/17/2014)... therapy improves general blood flow and alleviates muscle ... researchers at the University of Illinois at Chicago. ... print in the Archives of Physical Medicine ... vascular function in people who had not exercised, ... of their level of physical activity. , Improved ...
(Date:4/17/2014)... shocking rates of suicide are highest in areas with ... smallholdings less than one hectare and trying ... that are highly susceptible to global price fluctuations. , ... that point to a crisis in key areas of ... economy during the 90s. Researchers say that policy intervention ...
Breaking Medicine News(10 mins):Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:Massage therapy improves circulation, eases muscle soreness 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3
... the world's leading manufacturer and distributor of automated ... have its newest health station, the LC600 at ... be held at the Venetian Resort, Las Vegas, ... will be located in the Pharmacy of the ...
... July 3 The following is the,National Council ... The Bulletin, which is free of charge and ... you the latest issues and news affecting people ... to, http://listserv.access.gpo.gov, click on Online mailing list ...
... successfully introduced by P.-I. Brnemark and co-workers in ... years of research and development, titanium is currently ... titanium-based materials are often used to replace lost ... are some alternatives to modulating the body,s response ...
... Group, Inc. (MED3OOO), a,national leader in healthcare management ... has entered into a partnership,arrangement with Mitsui & ... & Co., Ltd. (Mitsui). The agreement with Mitsui ... of being a global "premier,strategic operations partner" for ...
... SAN FRANCISCO, Calif., July 3 Sunesis,Pharmaceuticals, Inc. (Nasdaq: ... Executive Officer and President, will provide a corporate,overview at ... p.m. Eastern Time on July 8, 2008 in New ... of the presentation by visiting,the Sunesis website at ...
... Therapeutics Inc.,("Transition" or the "Company") (TSX: TTH; NASDAQ: ... is pleased to announce that Mr. Elie,Farah has ... serve as,Chief Financial Officer, and Ms. Nicole Rusaw-George ... "These promotions reflect the strength of our ...
Cached Medicine News:Health News:Lifeclinic to Feature Latest Health Stations at McKesson's Pharmacy of the Future 2Health News:Lifeclinic to Feature Latest Health Stations at McKesson's Pharmacy of the Future 3Health News:Lifeclinic to Feature Latest Health Stations at McKesson's Pharmacy of the Future 4Health News:National Council on Disability Monthly Bulletin for June, 2008 2Health News:National Council on Disability Monthly Bulletin for June, 2008 3Health News:National Council on Disability Monthly Bulletin for June, 2008 4Health News:National Council on Disability Monthly Bulletin for June, 2008 5Health News:MED3OOO and Mitsui & Co. Complete U.S. and Global Healthcare Partnership Agreement 2Health News:MED3OOO and Mitsui & Co. Complete U.S. and Global Healthcare Partnership Agreement 3Health News:Transition Therapeutics Announces Executive Management Appointments 2
... Finnpipette Focus from Thermo Labsystems was designed ... Advanced features such as the new ... adjustment on microvolumes help to define this ... pipettes. The new interchangeable handle plate offers ...
This unique kit contains three pipettes conveniently packaged with useful accessoriesat an economical price....
... immunochromatography based one step in vitro test. ... and its metabolite in human urine,specimens. The ... a cut-off level of 300 ng/mL,can be ... in the point of care location and ...
... unique kit contains three pipettes ... an economical price. Three classic ... Two racks of certified-quality Diamond ... adhesive-backed Single Pipette Hangers 10 ...
Medicine Products: